

Richard Birnbaum
An Interview with a member
of Team Sherry Sharp

Boston Red Sox
Cure Alzheimer's Fund Night
at Fenway Park

NIH Funding
An increase in 2019
for AD research

CUREALZ UPDATE

FALL SEASON 2018

THE (R)EVOLUTION OF ALZHEIMER'S IN A DISH



Cure Alzheimer's FUND
targeting breakthrough research

Focused Research, Continued Growth

2018 has been an active and productive year so far, with both fundraising and research distribution on pace to exceed the extremely successful 2017. We have been growing at a compound average growth rate over the last three years for both contributions and research distributions of 25 percent!

As important as is the amount of money contributed and put into research, even more important is what that investment is buying. Summaries of the important discoveries our donors have helped to fund are featured in our 2017 Annual Report and on our website. The overall objective of this research is to learn how Alzheimer's pathology starts and progresses, and where it most effectively and efficiently can be disrupted.

The repeated failure of well-meaning and well-funded clinical trials, while good learning experiences, tell us that we do not yet know enough about the pathology of Alzheimer's disease to be placing these big clinical trial bets. We all hope for the best with these trials, but we also know that we need to learn more about the disease in order to make these pre-clinical efforts more productive. That's what Cure Alzheimer's Fund does.

On the national scene, we are heartened to see that funding for research through the National Institutes of Health into Alzheimer's disease has increased to \$2.2 billion per year. That is still against a staggering almost \$277 billion for care of Alzheimer's patients through Medicare, Medicaid and private insurance, but it's definitely heading in the right direction. See more on this in the "News in Brief" section.

We are delighted to welcome William Benter and Jay Jester to our Board of Directors. Bill has been a strong supporter of Alzheimer's research and we welcome him to the fight. Jay has

We are most grateful to the more than 12,000 donors who make this important research possible.

firsthand experience with the disease; his father passed away from Alzheimer's in 2017, and Jay is passionate about finding a cure. Please see biographies for Bill and Jay on our website.

This fall will be loaded with Cure Alzheimer's Fund activities, highlighted by our 8th Annual Science Symposium on Sept. 27 at Harvard Medical School's Joseph B. Martin Conference Center. We will be hosting a panel of three world-class researchers moderated by Jon Hamilton of National Public Radio.

As always, and never to be taken for granted, we are most grateful to the more than 12,000 donors who make this important research possible. With our Board members paying all the administrative costs for Cure Alzheimer's Fund, we are able to put every penny of every other contribution to work solving the very complicated and deadly mystery of Alzheimer's disease.

TIM ARMOUR
President and CEO

"Three years ago, my mother was diagnosed with dementia. She was one in a million and her struggle not only affected her but all those whose lives she touched.

"Last year, my family organized a garage sale and donated all the money to Cure Alzheimer's Fund. This year, my 16-year-old son, Jarrett, organized the garage sale with the help of our family. He asked his teachers at Bay Shore High School for any items they would like to donate. I am a teacher in the East Islip School District and the staff at my school donated garage sale items, as well. The garage was packed with donated items.

"Unfortunately, my mother passed away the week before the garage sale. She was 74 years young. The sale was postponed a few weeks because our family was in so much pain. Last week, we finally had the garage sale! In 90-degree heat, Jarrett hauled all the items to the front yard and with my husband and I. My sister brought more items and helped with the pricing. My younger son, Nate, sold lemonade. My mother would have been proud. She loved garage sales and she loved her family fiercely. Our family worked all day long to honor my mother, Kathy Locherer, and to help you to cure this dreadful disease. This is a devastating disease that affects so many people. Please take this money and find a cure!"

JENNIE NAGENGAST
Bay Shore, New York

News In Brief



'Daughter and Mother' Public Service Announcement

Award-winning social media film shown in more than 1,200 movie theaters nationwide

The two-minute film "Daughter and Mother" examines the profound and often-overlooked impact of Alzheimer's on caregivers. Created pro bono by BBDO New York for Cure Alzheimer's Fund, the work tells the heartbreaking story of a young girl tasked with caring for her sick mother, following the pair as they struggle with simple tasks made difficult by the mother's illness.

"The film highlights a few difficult truths about Alzheimer's disease—how it disproportionately affects women, both as individuals suffering with the disease and as caregivers, and its long-term impact," said Barbara Chambers, Senior Vice President of Cure Alzheimer's Fund.

Since its release in March, "Daughter and Mother" has received national and international attention. The short film was presented with a Silver Hugo Award by the 54th Annual Chicago International Television Festival and was named "Adweek" Ad of the Day in March. AMC, Regal and Cinemark were among the 1,200 theaters that played the PSA for a six-week period this spring on 16,000 movie screens and in lobbies in more than 200 markets.

Most recently, the film earned an award from the Association of Independent Commercial Producers. As

a result of the awards, "Daughter and Mother" is now a part of the archives of the Department of Film at MoMA (The Museum of Modern Art) in New York City.

"We are immensely grateful to BBDO Global Chief Creative Officer David Lubars for his insight and support, and to David Shane and the entire team at O Positive Films for their hard work and dedication," said Chambers. Lubars, also a private donor to Cure Alzheimer's Fund, lost his mother to Alzheimer's disease in 2013. CureAlz stands proudly behind this PSA and hopes its recognition leads to greater awareness of the devastation of Alzheimer's and the urgent need to find a cure.

Watch "Daughter and Mother" online at: vimeo.com/256946360.

The Brain Prize Winners

John Hardy, Ph.D., Bart De Strooper, M.D., Ph.D., Christian Haass, Ph.D., and Michel Goedert, M.D., Ph.D., were awarded the distinguished 2018 Brain Prize for their research on genetic conditions and disease mechanisms that are the basis of Alzheimer's disease.

The outstanding contributions of the prizewinners to neuroscience have

"provided a foundation for the design of drugs to counter the pathogenic process," said Prof. Anders Björklund, chairman of the Selection Committee, during the prize announcement.

Since 2011, the Lundbeck Foundation of Denmark has recognized the world's best neuroscientists for their groundbreaking impact on brain research with the annual \$1 million euro Brain Prize. The innovative work of Hardy, De Strooper and Haass around amyloid beta is funded by Cure Alzheimer's Fund.

NIH to Receive \$2.2 Billion in 2019 for Alzheimer's Research

The House Appropriations Committee in July approved a \$401 million increase in funding for Alzheimer's and dementia research at the National Institutes for Health for fiscal year 2019. If signed into law, funding would reach more than \$2.2 billion, a nearly fivefold increase since the passage of the National Alzheimer's Project Act in 2011.

"This is definitely heading in the right direction," said Tim Armour, President and CEO of Cure Alzheimer's Fund. "The reality is that care costs exceed \$277 billion for the 6 million Americans living with Alzheimer's and their 15+ million unpaid caregivers."

Due to increases in research funding, scientists are making progress toward the first goal of the national plan—to effectively treat and prevent Alzheimer's by 2025. The decision by the House Appropriations Committee is consistent with the request made by the NIH for total FY2019 funding.



THE (R)EVOLUTION OF ALZHEIMER'S IN A DISH

For decades, researchers have studied Alzheimer's disease searching for the causes that lead to the pathology and the eventual breakdown in cognitive ability for those who are affected. Replicating the disease in the lab was extraordinarily difficult using standard laboratory models.

Through a grant provided in 2014 by Cure Alzheimer's Fund, Rudolph Tanzi, Ph.D., and Doo Yeon Kim, Ph.D., of Massachusetts General Hospital created a new model called Alzheimer's in a Dish.

"Previous attempts at growing human brain cells in the lab and inducing them to form the plaques and tangles characteristic of Alzheimer's disease were performed in a two-dimensional Petri dish system. And, in this flat, 2-D environment, plaques and tangles simply didn't appear," said Dr. Francis Collins, director of the National Institutes of Health and leader of the Human Genome Project, in a 2014 blog post.


Kim had suggested growing human neural stem cells in a gel medium. The gel system allowed the cells to grow in a more natural 3-dimensional form.

This discovery caught the attention of researchers as well as the science media. In an October 2014 story, The New York Times wrote, "For the first time, and to the astonishment of many of their colleagues, researchers created what they call Alzheimer's in a Dish—a petri dish with human brain cells that develop the telltale structures of Alzheimer's disease. In doing so, they resolved a long-standing problem of how to study Alzheimer's and search for drugs to treat it; the best they had until now were mice that developed an imperfect form of the disease."

The article went on. "Of course, a petri dish is not a brain, and the petri dish system lacks certain crucial components, like immune system cells, that appear to contribute to the devastation once Alzheimer's gets started. But it allows researchers to quickly, cheaply, and easily test drugs that might stop the process in the first place."

For their work, Tanzi and Kim received the Smithsonian Ingenuity Award.

Now Tanzi and Kim, and Hansang Cho, Ph.D., of the University of North Carolina, Charlotte, have taken the model to a new and more comprehensive dimension.



Six days after activated microglia (red) were added to the outer chamber of the new microfluidic device, the inflammatory cells migrate through channels into the inner chamber, containing cultured neurons and astrocytes (green) with gene variants associated with familial Alzheimer's disease. Upon arrival in the inner chamber, the microglia directly attack neurons and raise levels of key inflammatory factors.

Credit: Joseph Park, Ph.D., Doo Yeon Kim, Ph.D., Rudolph E. Tanzi, Ph.D., and Hansang Cho, Ph.D.; Genetics and Aging Research Unit, Massachusetts General Hospital Institute for Neurodegenerative Disease.

Tanzi explains, "Our original 'Alzheimer's in a Dish' system recapitulated the plaques and tangles typically seen in the brains of patients with Alzheimer's disease, but did not induce neuroinflammation. Studies have shown that we can have many plaques and tangles in our brains with no symptoms, but when neuroinflammation kicks in, exponentially more neurons die and cognitive impairment leading to dementia is induced. A complete model of Alzheimer's pathology needs to incorporate that 'third leg of the stool.'"

Newsweek reported on the advancements in its August 2018 edition.


"This set-up provided an effective environment for the researchers to model the kind of neuroinflammation seen in Alzheimer's using human brain stem cells that had been modified to have a genetic disposition to the disease. Promisingly, with the help of their model, the team found that by blocking two receptors in microglial cells—glial cells that function as nervous system cells—they could prevent neuroinflammation, opening up new opportunities for the discovery of novel drugs." ■

ALZHEIMER'S FUNDAMENTALS:


Amyloid, Tau, Microglia: Astrocytes in the Human Brain

Research suggests that chronic inflammation may be caused by the buildup of glial cells normally meant to help keep the brain free of debris. One type of glial cell, microglia, engulfs and destroys waste and toxins in a healthy brain. In Alzheimer's, microglia fail to clear away waste, debris and protein collections, including amyloid beta plaques.

Astrocytes—another type of glial cell—are signaled to help clear the buildup of plaques and other cellular debris left behind. These microglia and astrocytes collect around the neurons but fail to perform their debris-clearing function. In addition, they release chemicals that cause chronic inflammation and further damage the neurons they are meant to protect.



National Institute on Aging, NIH

A man with glasses and a goatee, wearing a dark jacket, stands on a rooftop garden set. He is gesturing with his hands while speaking. In the background, there are city buildings, a red triangular sign, and a blue wall. A boom microphone is visible above him, and a camera is in the foreground on the left.

A Q&A WITH RICHARD BIRNBAUM

Richard Birnbaum was with Circuit City Stores for more than 30 years. He served as Executive Vice President and was a member of CEO Richard Sharp's leadership team that grew Circuit City to be a more than \$10 billion powerhouse and started CARMAX, the largest used car retailer in the United States. Today, Richard puts his expertise to work primarily through V-Ten Capital Management and for the Rick Sharp Alzheimer's Foundation.

Hi, Richard. Will you tell us about Rick Sharp?

First and foremost, Rick was a terrific human being and wicked smart. He was all about family, friendships, doing the right thing, making it fun, perspective, speed, philanthropy, community leadership, competition and winning! Rick was truly a visionary, venture capitalist and entrepreneur. He passed away in 2014 from a rare form of Alzheimer's disease called posterior cortical atrophy. He would be very proud of the work his wife, Sherry, does on the board of the Cure Alzheimer's Fund, believing in their approach to finding a cure.

Tell us about his wife, Sherry.

Sherry was Rick's high school sweetheart and wife for 45 years. She has dedicated herself to working to find a cure for this dreadful disease. Sherry is one of the kindest people I know—and the most determined person ever to rid the world of Alzheimer's. Alzheimer's is relentless and so is Sherry! Sherry also adores being part

of the lives of her four grandchildren, two daughters and their husbands.

How did you come to know Rick?

I met Rick when he joined Circuit City in the '80s. Rick retired from CC in the late '90s, and I did the same a few years later. We continued to work together after that on a number of projects. Jim Karides and Cheri Jennings also knew and worked with Rick for decades. Our "Team Sharp" is still together with Sherry. I was, and still am, honored to be part of 30+ years of Rick's amazing endeavors. All our families have shared many experiences and lifecycle events together over the years. My wife, Shelley, loved Rick, is a friend of Sherry's and the family, and takes a lead role in our fundraising events.

It's a tribute to Richard, Sherry and the Sharp family that we have had such an outpouring of support and donations to see Alzheimer's cured.

How did the Richard Sharp Family Foundation get involved with Cure Alzheimer's Fund?

Rick was all too aware that he had Alzheimer's and was courageous in going public about wanting to make a difference in finding a cure, [even if] not in time for himself, but for his four grandchildren and society. Sherry and Team Sharp began vetting institutions and organizations when Sherry Sharp and Cheri Jennings met two of the founders, Jeff and Jacqui Morby, fortuitously through other local Richmond friends. Traveling to Boston, we got to meet the leadership team, including Dr. Rudy Tanzi, and learned that Cure Alzheimer's Fund was doing exactly what we had envisioned. That is, with the world's best and brightest funding a

continued on page 11



ALZHEIMER'S DAY IN RVA

November 14, 2018

Science Museum of Virginia • 2500 W. Broad St., Richmond

**Finding a Cure and Prevention
10:30 A.M.—1:30 P.M.**

Symposium, Saks Fifth Avenue
Fashion Show and Luncheon
Fantastic Door Prizes

**Dr. Rudy Tanzi on "State of the Mind"
5 P.M.—7:30 P.M.**

Conversation with Rudy Tanzi, Ph.D.,
and Cheers for a Cure Reception
Showcase Silent Auction

TO BENEFIT CURE ALZHEIMER'S FUND

FOR TICKET SALES, SPONSORSHIP AND DONATIONS CONTACT:

Carli Nelson, Donor Engagement
carli@ricksharpalz.org • 833.CURE ALZ (Toll Free)



CURE ALZHEIMER'S FUND NIGHT AT THE RED SOX

On June 5 the Boston Red Sox hosted Cure Alzheimer's Fund at the team's game against the Detroit Tigers to raise awareness about Alzheimer's disease and efforts to identify effective treatment and prevention strategies.

The event included a ceremony on the Fenway Park field honoring a number of our researchers who are working to better understand and find a cure for Alzheimer's disease. Cure Alzheimer's Fund

Co-Chairs Jeff Morby and Henry McCance also participated in the ceremony, along with a color guard

composed of members of the Quincy Fire Department, Fire Fighters Local 792, who hold an annual fundraising event for us.



During the ceremony, the Cure Alzheimer's Fund new public service announcement played on the park's big screen, along with information about the impact of Alzheimer's disease on those with it, as well as their friends and families.

The first pitch was thrown by Dr. Rudy Tanzi, who was followed on the field by six youngsters affiliated with Cure Alzheimer's Fund who began the contest with the familiar "Play Ball!" Additionally, Morby, McCance and Tanzi were interviewed live on the New England Sports Network before the game.

The event helped honor researchers who are focused on the science that could lead to a cure or effective treatments. This was a special gift that provided Cure Alzheimer's Fund an opportunity to educate Red Sox fans on how they can be a part of the fight to cure the disease. All of us at Cure Alzheimer's Fund are enormously grateful to the Red Sox for their generosity and support. ■



Heroes Spotlight

The Sarabande Dance Ensemble at Tufts University in Boston chose to donate proceeds from its spring concert to CureAlz. Freshman dancer **Gabrielle de Weck** nominated CureAlz and shared with the audience at the April performance about the cause that is close to her heart. ■ Sponsors pledged \$10 for every axel jump landed at the June Axels for Alzheimer's figure skating show held in Natick, Massachusetts. Organized

by **Leah Spencer**, the event featured national and regional guest stars, who entertained guests with their on-ice skills and 32 axel jumps. ■ This was the third year **Lt. Ralph Blight** and International Association of Firefighters (IAFF) Local 792 in Quincy, Massachusetts, held a bowling event at Olindy's to raise money for CureAlz. ■ **Tracy Holland** and **Mambo Room** in Norfolk, Virginia, hosted its

DOUBLEDOWN FOR RESEARCH • ONLINE

JACKPOT! **DoubleDown Interactive** reached its goal of \$20,000 in donations during a June online fundraiser to benefit Cure Alzheimer's Fund.

Sponsored by its flagship title application, DoubleDown Casino is a social gaming casino that offers more than 60 different games, including slots, video poker, blackjack and roulette. Player chip purchases during the three-day campaign counted toward the goal.

"Donations from online gaming are a first for us," said Laurel Lyle, Vice President, Development Operations and Fundraising Programs for Cure Alzheimer's Fund. "We are most appreciative to DoubleDown Interactive for promoting our cause, and for its generous donation."


MORELS & MEMORIES • WATERTOWN, MINNESOTA



Morel mushroom aficionados gathered in Watertown, Minnesota, in early May to forage for the fervently pursued fungi at **The Morels & Memories Mushroom Hunt & Alzheimer's Fundraiser**.

As event founder Courtney Iverson noted on the hunt's website, "I started this in honor of my mother, Heidi Vanderlinde, who was diagnosed with younger-onset Alzheimer's disease in 2011 at the age of 49." The fundraiser is now in its third year, with all proceeds going to fund vital research through Cure Alzheimer's Fund.

Because the prized morel is a wild mushroom that cannot be cultivated, the exact location of the hunt was closely guarded and not disclosed until the night before the event. In addition to morel hunting, the half-day event featured insider tips and tricks on locating morels, and prizes for the first, largest and most found. Executive Chef Ken Koegler held a morel cooking demonstration and sampling while participants were entertained by the music of Jazziblu.



10th annual Dance for a Cause Dance-a-thon in May—12 nonstop hours of salsa, bachata, swing, international performers and a whole lot of dancing to support our cause and other worthy charities. ■ Find A Cure Today (FACT) was created by Denver's **Antonella Pisani** and **Scott Laverty**, who launched **FACT Goods**, a line of inspirational clothing. They will donate 25 percent of proceeds to charitable organizations, including CureAlz. ■ Carriage House at Lee's Farm, a Northbridge senior residence, and the Wayland (Massachusetts) Police Department celebrated **National Chili Day** in February with residents by hosting a chili cook-off fundraiser. ■ Professional a cappella groups from around the world performed with collegiate and high school ensembles at the 16th annual **SingStrong** A cappella Festival founded by **Jonathan Minkoff**. The event was held at Adelphia University Performing Arts Center in New York and included a silent auction to benefit CureAlz. ■ **Piper Lou Cares** donates 100 percent of the net profits associated with product sales to its specified cause. Check out their tees, tumblers and more online! ■ **One American Charity Ride** is a three-month-long, cross-country bicycling fundraiser started by **Robert Kiss**. The 60-year-old Kiss began his journey in San Diego and finished at the Statue of Liberty. Segments of the ride were devoted to CureAlz and 25 other charities. Throughout his journey, Kiss pedaled 3,704 miles, climbed more than 136,865 feet and raised \$103,000.



Financial Update

JANUARY 2018 — JUNE 2018

Numbers shown are preliminary for the period and are rounded to the nearest \$100,000.

	YTD	Inception to Date
Fundraising	\$9.4M	\$103.9M
Expenses paid for by the board	\$1.6M	\$19.9M
Research spending	\$4.1M	\$71.2M

Research Projects

	Distribution Amount
Imaging Microglial Homeostasis and Disruption: P2RY12 Radiotracer Development (Year 1) Jacob M. Hooker, Ph.D., and Michael S. Placzek, Ph.D., Massachusetts General Hospital	\$172,500
PICALM Gene Therapy and Drug Screening for Amyloid Beta Clearance (Year 3) Berislav V. Zlokovic, M.D., Ph.D., University of Southern California	\$300,000
Targeting Beneficial Innate Immunity in Alzheimer's by Interleukin-1 Receptor-Associated Kinase M Deletion (Year 3) Terrence Town, Ph.D., University of Southern California	\$172,500
Temporal Analysis of Infection in Alzheimer's Disease Models Judith Steen, Ph.D., Boston Children's Hospital	\$149,999
Rejuvenation of Microglia in Brain Aging and Neurodegeneration (Year 3) Tony Wyss-Coray, Ph.D., Stanford University	\$172,500
Role of Ataxin-1 in Regulating BACE1 Activity (Year 2) Jaehong Suh, Ph.D., Massachusetts General Hospital	\$287,500
Scientific Directions for the Exploration of Racial Disparities in Alzheimer's Disease Krista L. Moulder, Ph.D., Washington University School of Medicine	\$79,594
Genetic Targets to Block Tau Propagation: Test Knockdown of HSPG Genes <i>in Vivo</i> (Year 3) Marc Diamond, M.D., University of Texas Southwestern Medical Center	\$172,500
The Role of Neurexins in Alzheimer's Disease (Year 2) Rudolph Tanzi, Ph.D., and Meng Chen, Ph.D., Massachusetts General Hospital	\$172,500
Evaluation of Sleep-EEG in Transgenic Mice G2T™ (Year 2) PsychoGenics	\$27,500
Evaluation of the Effect of Cell Type-specific Deletion of ESCRT Genes on the Spread of Tau Pathology (Year 1) Tsuneya Ikezu, M.D., Ph.D., Boston University	\$172,500
Neurotoxic Reactive Astrocytes in Alzheimer's Disease (Year 1) Shane A. Liddelow, Ph.D., New York University Langone Medical Center	\$250,000
Interpretation of Noncoding Risk Alleles for Alzheimer's Disease (Year 1) Christopher K. Glass, M.D., Ph.D., University of California, San Diego	\$250,000
Assessing the Links Between the Ms4a Risk Genes, Microglia and Alzheimer's Disease (Year 1) Sandeep Robert Datta, M.D., Ph.D., Harvard Medical School	\$250,000
Neuroimmune Molecular Imaging: Redefining the Landscape of Opportunities in Alzheimer's Disease Jacob M. Hooker, Ph.D., Massachusetts General Hospital	\$100,000
Microglial Heterogeneity and Transcriptional State Changes in Alzheimer's Disease (Year 1) Beth Stevens, Ph.D., Boston Children's Hospital	\$299,924
Development and Breeding of Mice Models for Genes to Therapies™ Research Projects Taconic	\$1,049,634

A Q&A WITH RICHARD BIRNBAUM

continued from page 7

venture capital/philanthropic mindset for meaningful research—and doing it really well. Sherry and Team Sharp were so impressed with the CureAlz Fund mission and leadership that she agreed to join the Board In 2014; our “Team Sharp” is quick to lend any support we can to such a great cause in Rick’s memory.

Tell us about the work of RSAF.

We created the RSAF to raise additional funds to help cure Alzheimer’s disease. It’s the umbrella under which we try different types of events. To date, we’ve donated over \$1.5 million to CureAlz Fund research from our two Rick Sharp Classic events. It’s a tribute to Richard, Sherry and the Sharp family that we have had such an outpouring of support and donations to see Alzheimer’s cured. To make it all happen, we have a small but mighty team of volunteers—including, from the beginning, Karen Adams, a friend and Circuit City alum.

What type of events did you run?

In June of 2016 and ‘17 we ran the “Rick Sharp Classic”—an evening silent and live auction followed by a golf tournament the next day. We were very pleased with the results, doubling [in] our second year and we’re grateful to our community for their support. It also was becoming clearer that not just “friends and family” wanted to both participate and support research in Rick’s memory, but they also wanted to learn more about this horrible disease.

For the 2018 event, you’re doing something totally different. Tell us about it.

This year, we are presenting “ALZHEIMER’S DAY IN RVA” (Richmond, Virginia), a daylong event that will include morning and evening research symposiums, a luncheon, fashion show and small silent and live auction at the Science Museum of Virginia on November 14. I’m really excited that with the help of the CureAlz

Fund team we are bringing Rudy Tanzi, Chair of the CureAlz Research Leadership Group, and other funded scientists to Richmond. You can contact us directly at 833-CURE ALZ (833-287-3259) toll free or email carli@ricksharpalz.org for more information.

What would you like our readers to know about your work with Sherry and Team Sharp?

Rick’s diagnosis was a huge motivator for us to learn as much as possible about this unforgiving disease and go do something about it. Sherry, Jim, Cheri and I have challenged ourselves to think out of the box and look at how we can make a difference in helping rid the world of Alzheimer’s. I’ve had the opportunity to work with exceptional people at the CureAlz Fund. I’m proud, both personally and professionally, of the work they are doing and to be a part of it. ■



MISSION:

Fund research with the highest probability of preventing, slowing or reversing Alzheimer’s disease.

BOARD OF DIRECTORS

JEFFREY L. MORBY

Co-Chairman, Founding Board Member

HENRY F. McCANCE

Co-Chairman, Founding Board Member

TIM ARMOUR

President and CEO

BILL BENTER

Board Member

ROBERT F. GREENHILL

Board Member

JAY JESTER

Board Member

JACQUELINE C. MORBY

Founding Board Member

PHYLLIS RAPPAPORT

Treasurer, Founding Board Member

SHERRY SHARP

Board Member

Charity Designation – Cure Alzheimer’s Fund is a “doing business as” name for the Alzheimer’s Disease Research Foundation, a 501(c)(3) public charity with federal tax ID #52-239-6428.

MAIN OFFICE

34 Washington St., Suite 200
Wellesley Hills, MA 02481
Phone: (781) 237-3800
info@curealz.org

OFFICE OF THE CO-CHAIRMAN

Centre City Tower
650 Smithfield St., Suite 2015
Pittsburgh, PA 15222
Phone: (412) 261-2785

CUREALZ UPDATE

FALL SEASON 2018

Copy Editor: Colleen O'Neill
Design and Layout: Winking Fish
Printing and Mailing: Universal Wilde



8TH ANNUAL SCIENTIFIC SYMPOSIUM

THE CASE FOR HOPE:

Progress with the Research of Alzheimer's Disease

Thursday, September 27, 2018

The Joseph B. Martin Conference Center
at Harvard Medical School
77 Avenue Louis Pasteur, Boston

5:30 p.m. – **Panel Discussion**

7:00 p.m. – **Closing Reception**

Open to all symposium attendees

OUR PANELISTS



Jon Hamilton
NPR Correspondent, Science Desk



Teresa Gomez-Isla, M.D.
Massachusetts General Hospital



Ronald C. Petersen, M.D., Ph.D.
Mayo Clinic



Robert Vassar, Ph.D.
Northwestern University

RSVP

Please join us. Space is limited and there is no admission fee.

To register, visit CureAlz.org/Symposium, or contact
Kristen Hawley at **781-943-3335** or khawley@CureAlz.org.

If you cannot attend in person, a live stream of the research
presentation will be available online at CureAlz.org/2018symposium
starting at 5:30 p.m. There is no need to register for the live stream.



CureAlz.org | WomenandAlzheimers.org